Phase 1 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
All participants:
- People who give their written agreement to take part before any study-related activities begin
- Men, or women who are not able to become pregnant
Healthy participants:
- People aged 18 to 45 years old at the time of signing the consent form
- People whose Body Mass Index (BMI) falls between 18.5 and 29.9 at the screening visit
- People whose blood sugar control measure (HbA1c) is 6.4% or below at the screening visit
- People considered to be in general good health based on their medical history, physical check-up, heart tracing, and blood tests, as assessed by the study doctor
Participants with Type 2 Diabetes:
- People aged 18 to 64 years old at the time of signing the consent form
- People whose BMI falls between 20.0 and 34.9 at the screening visit
- People whose HbA1c blood sugar measure falls between 6.5% and 8.5% at the screening visit
- People who were diagnosed with type 2 diabetes at least 180 days before the screening visit
- People who have been taking a stable daily dose of metformin for at least 90 days before the screening visit
Who may not be able to join:
All participants:
- People whose liver enzyme levels (ALT, AST) or bilirubin levels are above the accepted normal range at screening
- People whose kidneys are not filtering blood well enough, based on a specific kidney function test result below a certain threshold at screening
- People with signs or a history of chronic kidney disease, or whose urine test shows a protein level above the accepted limit
- People who have, or have previously had, heart or blood vessel conditions — including chest pain (stable or unstable), heart attack, mini-stroke, stroke, heart failure, significant irregular heartbeat, or significant problems with the heart's electrical signalling
Healthy participants only:
- People who have any other health condition that the study doctor believes could affect their safety or ability to follow the study rules
- People whose resting blood pressure at screening falls outside the range of 90–139 (upper number) or 50–89 (lower number) mmHg
Participants with Type 2 Diabetes only:
- People who have any other health condition beyond mild, stable conditions related to their diabetes, that the study doctor believes could affect their safety or ability to follow the study rules
- People whose resting blood pressure at screening falls outside the range of 90–159 (upper number) or 50–99 (lower number) mmHg — this applies even to those already taking blood pressure medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency dept. 2834, Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of treatment emergent adverse events (TEAEs); Number of hypoglycaemic events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.